EA201792325A1 - Способ увеличения процентного содержания мономерного антитела в fab-dsfv мультимерных частицах - Google Patents

Способ увеличения процентного содержания мономерного антитела в fab-dsfv мультимерных частицах

Info

Publication number
EA201792325A1
EA201792325A1 EA201792325A EA201792325A EA201792325A1 EA 201792325 A1 EA201792325 A1 EA 201792325A1 EA 201792325 A EA201792325 A EA 201792325A EA 201792325 A EA201792325 A EA 201792325A EA 201792325 A1 EA201792325 A1 EA 201792325A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
increasing
monomarian
dsfv
fab
Prior art date
Application number
EA201792325A
Other languages
English (en)
Russian (ru)
Inventor
Сэм Филип Хейвуд
Гэвин Барри Уайлд
Кристофер Джон Ле Пейдж
Разван Ханиф
Original Assignee
Юсб Биофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Биофарма Спрл filed Critical Юсб Биофарма Спрл
Publication of EA201792325A1 publication Critical patent/EA201792325A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201792325A 2015-04-22 2016-04-22 Способ увеличения процентного содержания мономерного антитела в fab-dsfv мультимерных частицах EA201792325A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506869.5A GB201506869D0 (en) 2015-04-22 2015-04-22 Method
PCT/EP2016/059050 WO2016170137A1 (en) 2015-04-22 2016-04-22 Method for increasing the percentage of monomeric antibody fab-dsfv multimeric species

Publications (1)

Publication Number Publication Date
EA201792325A1 true EA201792325A1 (ru) 2018-04-30

Family

ID=53299018

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792325A EA201792325A1 (ru) 2015-04-22 2016-04-22 Способ увеличения процентного содержания мономерного антитела в fab-dsfv мультимерных частицах

Country Status (16)

Country Link
US (2) US10829565B2 (enExample)
EP (1) EP3286220A1 (enExample)
JP (1) JP6901402B2 (enExample)
KR (1) KR20170138551A (enExample)
CN (1) CN107683290B (enExample)
AU (1) AU2016251960A1 (enExample)
BR (1) BR112017022472A2 (enExample)
CA (1) CA2983537A1 (enExample)
CL (1) CL2017002677A1 (enExample)
CO (1) CO2017010845A2 (enExample)
EA (1) EA201792325A1 (enExample)
GB (1) GB201506869D0 (enExample)
IL (1) IL255094A0 (enExample)
MX (1) MX2017013419A (enExample)
SG (1) SG11201708430VA (enExample)
WO (1) WO2016170137A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
MY190770A (en) * 2016-12-09 2022-05-12 Ose Immunotherapeutics Antibodies and polypeptides directed against cd127

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4877868A (en) 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP2007536898A (ja) 2003-07-01 2007-12-20 セルテック アール アンド ディ リミテッド 修飾抗体Ｆａｂフラグメント
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
GB0425534D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
CA2622441A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
US20090269343A1 (en) 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
US20110144311A1 (en) 2008-08-14 2011-06-16 Rebecca Chmielowski Methods for purifying antibodies using protein a affinity chromatography
JP2012503487A (ja) * 2008-09-26 2012-02-09 シェーリング コーポレイション 高力価抗体の製造
CN102164965B (zh) * 2008-09-26 2016-03-30 Ucb医药有限公司 生物产品
US9464138B2 (en) * 2009-04-30 2016-10-11 Ablynx N.V. Method for the production of domain antibodies
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201001791D0 (en) * 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
ES2717883T3 (es) 2010-03-25 2019-06-26 Ucb Biopharma Sprl Moléculas de DVD-LG estabilizadas con disulfuro
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US9150663B2 (en) * 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
KR101860963B1 (ko) * 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
WO2012140214A1 (en) 2011-04-13 2012-10-18 Biomay Ag IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES
WO2013055958A1 (en) * 2011-10-11 2013-04-18 Genentech, Inc. Improved assembly of bispecific antibodies
BR112014011304B1 (pt) * 2011-11-11 2022-03-03 UCB Biopharma SRL Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2822597A1 (en) 2012-03-09 2015-01-14 UCL Business Plc. Chemical modification of antibodies
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AU2014325063B2 (en) * 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN108026165A (zh) 2015-08-17 2018-05-11 鲁平有限公司 用于抗体碎片的改进的复性方法

Also Published As

Publication number Publication date
US11834514B2 (en) 2023-12-05
IL255094A0 (en) 2017-12-31
CN107683290A (zh) 2018-02-09
KR20170138551A (ko) 2017-12-15
JP6901402B2 (ja) 2021-07-14
WO2016170137A1 (en) 2016-10-27
JP2018515453A (ja) 2018-06-14
EP3286220A1 (en) 2018-02-28
SG11201708430VA (en) 2017-11-29
BR112017022472A2 (pt) 2018-07-17
US20180142039A1 (en) 2018-05-24
MX2017013419A (es) 2018-02-09
CO2017010845A2 (es) 2018-03-20
CA2983537A1 (en) 2016-10-27
CN107683290B (zh) 2022-01-04
US20210079120A1 (en) 2021-03-18
US10829565B2 (en) 2020-11-10
CL2017002677A1 (es) 2018-03-23
GB201506869D0 (en) 2015-06-03
AU2016251960A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
EA201792325A1 (ru) Способ увеличения процентного содержания мономерного антитела в fab-dsfv мультимерных частицах
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PE20170665A1 (es) Anticuerpos anti-tau humanizados
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
PE20180499A1 (es) Anticuerpos de union a tau
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
MY201701A (en) Optimized antibody compositions for treatment of ocular disorders
PE20190261A1 (es) Anticuerpos que reconocen tau
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
UA123202C2 (uk) Антитіло до тау-білка і його застосування
EA202091747A1 (ru) Составы антитела b7-h4
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PH12019502298A1 (en) Monoclonal antibody to pd-l1
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
EA201990895A1 (ru) Антитела к о1 и варианты их применения